Trial Profile

Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AUTO 2 (Primary) ; AUTO-3 (Primary) ; AUTO-4 (Primary) ; Obecabtagene autoleucel (Primary)
Indications Diffuse large B cell lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
Focus Adverse reactions
Sponsors Autolus

Most Recent Events

03 Feb 2023 Planned End Date changed from 1 Dec 2032 to 1 Dec 2043.
03 Feb 2023 Planned primary completion date changed from 1 Jul 2032 to 1 Jul 2043.
08 Aug 2019 According to an Autolus media release, the company expects to present data from the study at ASH 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com